The Centers for Medicare and Medicaid Services has agreed on a payment of up to $1,040 per use of the algorithm in patients with suspected LVO. 

Swedish researchers test drove three commercially available AI algorithms and found wide variance, sharing their results in JAMA Oncology. 

Also, RSNA reveals virtual exhibition details, Change acquires Nucleus.io and the FDA clears two artificial intelligence offerings from Siemens. 

Also, Nanox eyes $125 million IPO, Philips inks multi-year MRI research pact, and Zebra Medical teams up with Canon USA. 

The latest comes for Zebra Medical's HealthMammo algorithm, which helps radiologists pinpoint and prioritize suspicious breast images.

“Cina Head,” as the solution is called, aids docs with the automatic detection of hemorrhaging inside of the skull or a clot blocking the flow of blood to the brain, the company said. 

MammoScreen, as it’s called, operates by automatically detecting and characterizing suspicious soft tissue lesions and calcifications. 

Top officials from the two groups believe it’s unlikely the FDA can provide assurances of such technology’s safety in imaging care, absent further testing, surveillance and other methods of oversight.